Summary Microvessel density of benign, borderline and malignant ovarian tumours was studied immunohistochemically using antibodies to the endothelial cell markers CD31, CD34 and factor VIII-related antigen. Microvessel density was compared in tumours of different histological subtype, stage and patient outcome. CD31 -immunostained sections were examined and regions of high and average microvessel density were selected. Identical regions were located on CD34-and factor Vill-related antigen-immunostained serial sections and microvessel counts obtained and converted to vessels mm-2. CD31 and CD34 immunostaining revealed increased microvessel density in both the high and average vessel density regions of mucinous (222.4 ± 24.8; 79.9 + 8.5) compared with serous (105.4 + 20.7; 33.3 ± 6.8) and benign (84.4 + 19.4; 20.4 + 4.4) tumours (P < 0.001). CD31 and CD34 immunostaining also revealed increased microvessel density in early-stage mucinous tumours (234.6 ± 28.2; 87.8 + 9.2) compared with that observed in both early-(72.8 + 15; 12.9 ± 2.4) and late-(115.6 ± 26.5; 29.8 + 8.5) stage serous tumours (P < 0.001). No differences in microvessel density in samples from patients with differing outcomes were observed (P > 0.05). Reduced factor VIII-related antigen compared with CD31 and CD34 immunostaining was observed in both borderline and malignant mucinous and serous tumours (P < 0.02) but not in benign tumours (P > 0.05). Our results contradict the putative association between increased microvessel density and poor prognosis and suggest that the level and control of angiogenesis may differ between ovarian tumour types.
Epithelial ovarian cancer is a common gynaecological malignancy. Most patients are diagnosed in the advanced stages of the disease and 5-year survival rates are, at approximately 20%, quite low (Kristensen and Trope, 1997) . Angiogenesis, or the growth of new blood vessels, is essential for the development, growth and spread of solid tumours (Folkman, 1985) . Measurements of microvessel density (MVD) are often used to indicate tumour angiogenesis, and two of three recent studies of MVD in ovarian carcinoma have demonstrated an association between increased MVD and reduced patient survival (Hollingsworth et al, 1995; van Diest et al, 1995; Gasparini et al, 1995) .
Most ovarian neoplasms arise from the epithelium of the ovary and may be benign, malignant or borderline (low malignant potential tumours). Epithelial ovarian tumours are staged (I-IV) according to tumour spread, and a number of histological subtypes exist, including serous, mucinous, endometrioid, clear cell, transitional cell and mixed epithelial (Kristensen and Trope, 1997) . In this study we quantified MVD in benign tumours and in borderline and malignant tumours of the serous and mucinous types. Malignant serous tumours are generally diagnosed at later stages and survival rates are low. Mucinous tumours are generally early-stage, borderline tumours and patients diagnosed with these tumours have a more favourable outcome (Kristensen and Trope, 1997) . The first aim of this study was to compare microvessel density in benign, mucinous and serous tumours and to relate this to the prognosis of these tumour types.
An association between elevated MVD and patient prognosis has been demonstrated in many tumour types, although other studies have failed to repeat these observations (reviewed in Weidner, 1995) .
Heterogeneity of the tumour vasculature is well recognized (Weidner et al, 1991; Visscher et al, 1994) and most prognostic studies evaluate MVD in regions of high microvessel density or areas termed vascular 'hotspots'. These regions are not only thought to represent regions of ongoing tumour angiogenesis but also to be the site of tumour cell entry into the circulation (Rak et al, 1995a; Weidner, 1995) . However, rather than spreading via the vasculature, ovarian tumours generally spread by peritoneal dissemination (Kristensen and Trope, 1997) and tumour angiogenesis is unlikely to play a role in this type of spread. The growth of the primary ovarian tumour and its peritoneal metastases is dependent on continued blood vessel growth (Sheid, 1992) , and regions other than vascular 'hotspots' may contribute to this growth. Thus, the second aim of this study was to compare MVD in both high vessel density (HVD) and average vessel density (AVD) regions of ovarian tumours of differing prognosis.
A variety of endothelial cell markers can be used to highlight tumour blood vessels immunohistochemically. The most commonly used antibodies include those to factor VIII-related antigen, CD31 and CD34. Factor VIII forms part of the von Willebrand factor complex and plays a role in the coagulation process (Fay, 1993) . CD3 1, also known as platelet-endothelial cell adhesion molecule, is a transmembrane glycoprotein involved in cell-cell adhesion (DeLisser et al, 1994) and CD34 is a surface glycoprotein of unknown function (Krause et al, 1996) . The relative abilities of these antibodies to highlight the vasculature has been examined in a number of tumours (Kuzu et al, 1992; Toi et al, 1993) , and the final aim of our study was to compare the microvessel staining abilities of these commonly used endothelial cell markers in ovarian tumours.
MATERIALS AND METHODS
Tissue specimens Specimens from benign, malignant and borderline primary ovarian tumours were assessed. Only one block from each tumour was with PBS again and incubated with horseradish peroxidaseconjugated streptavidin (Zymed). After washing with PBS, the colour was developed by incubating the sections with 3-amino-9-ethylcarbazole (Zymed) for 10 min. Sections were then washed with water, counterstained with haematoxylin and mounted with Clearmount (Zymed) mounting medium.
Microvessel quantification
Sections were analysed using a Zeiss Axioskop microscope, and the images projected to a Sony PVM1440QM video monitor using a Sony CCDIRIS video camera. A preliminary examination of the slides indicated that CD31 antibody gave the most sensitive and specific staining of endothelial cells. In contrast, stromal elements of some tumours were CD34 positive and FVIII-RA antibody appeared to stain fewer microvessels. Therefore sections stained for CD3 1 were used to select HVD and AVD regions. The sections were scanned at low power to locate regions of high MVD and counts were obtained for these regions (100 x magnification, 0.29 mm2 field size). The region with the highest microvessel count was selected and its location within the section noted. The average vessel density region was selected by scanning the section (100 x magnification) and obtaining microvessel counts for up to 20 fields. The average number of vessels per field was calculated and a region representative of this average was selected. Vessels were defined as any positively stained single cell or cluster of cells. The presence of a lumen was not a defining characteristic. The same region on serial sections stained for CD34 and FVIII-RA was located and microvessel counts obtained. Vessel counts per field were converted to vessels mm-2.
Statistics
All statistics were performed using the SPSS statistics package (V6. 1.2; SPSS Australasia, North Sydney, NSW, Australia). Vessel density measurements were transformed to obtain homogeneity of variance if required and ANOVA conducted. Multiple comparisons were performed using the Bonferroni t-procedure. For single comparisons the data were transformed appropriately and Student's t-test performed. The criterion of statistical significance applied was P < 0.05.
RESULTS

Qualitative differences in blood vessel immunostaining
Vessel density within each tumour section was heterogeneous, readily allowing HVD and AVD regions to be distinguished from each other and from relatively avascular regions. This was evident with all vessel markers tested in this study despite differences in their endothelial cell staining ability (Figure 1 ). IgG and rabbit serum negative control slides were clear of immunostaining. Differences in the nature of the staining seen with each antibody were apparent. CD34 staining was generally localized to endothelial cells; however, stromal staining was observed in some samples, particularly those from benign tumours. FVIII-RA staining was frequently of a granular appearance. In some of the more vascular malignant tumours and in the high vessel density regions of some of the less vascular tumours CD3 1 appeared to be localized to the endothelial cell boundary, giving the vessels a striped appearance (Figure 1) MVD given as vessels mm-2 (mean ± s.e.m.). aFVIII-RA immunostaining is significantly less than that seen with DC31 and CD 34 (ANOVA; P < 0.02);b FVIII-RA immunostaining is significantly less than that seen with CD31 (ANOVA; P < 0.001).
British Journal of Cancer (1998) 77(12) (Rak et al, 1995b) . Although mutation of this gene is frequently observed in mucinous tumours, it rarely occurs in serous ovarian tumours (Fujita et al, 1994) . In contrast, mutation of the tumour-suppressor gene p53 is more frequently observed in serous ovarian tumours (Fujita et al, 1994) and may be associated with down-regulation of the angiogenesis inhibitor thrombospondin-I (Dameron et al, 1994 Previous studies examining MVD in ovarian carcinoma have used ler microvessels than antibody survival curves to assess the prognostic ability of MVD, and two < 0.0001; Table 2 ). In serous of these three studies demonstrated an association between higher ipared with CD31 immuno-MVD and reduced survival (Hollingsworth et al, 1995; van Diest -stage tumours (ANOVA; P < et al, 1995; Gasparini et al, 1996) . Small group numbers and FVIII-RA immunostaining in shorter follow-up times precluded the use of this technique in the tly different from that obtained current study. As an alternative, we compared MVD in serous (ANOVA; P > 0.05; Table 2 ). nostic indicator in ovarian tumours is only applicable to late-stage ours has been reported previtumours, a group in which haematogenous spread may occur ever, in this study most of the (Kristensen and Trope, 1997) . In the previous studies of MVD in e tumours, and the increased ovarian tumours, in which an association between increased MVD ssociated with the poorer progand reduced survival has been demonstrated (Gasparini et al, other histological types. In the 1996; Hollingsworth et al, 1995) , most of the tumours have been mucinous tumours were earlyof the late-stage serous type. ith a good prognosis. Thus, the In the current study MVD in benign ovarian tumours was similar mucinous tumours relative to to that seen in malignant serous tumours, suggesting that a similar rous tumours seems to contralevel of angiogenesis is occurring in these two tumour groups. -en increased MVD and poor Microvessel density in benign ovarian tumours has not been exam- (Hollingsworth et al, 1995;  ined previously; however, these tumours can attain quite large sizes (Deligdisch, 1994) and would be expected to induce an angiogenic t and borderline mucinous and response to accommodate this growth. Expression of both VEGF the oncogene K-ras has been and PDECGF has been demonstrated in benign ovarian tumours the angiogenic factor vascular (Reynolds et al, 1994) . Parallels between tumour angiogenesis, Microvessel density in tumours of the ovary 2209 tumour invasion and metastasis have been suggested (Liotta et al, 1991; Rak et al, 1995a) and in some tumours the same mechanism is thought to govern these processes. However, the similarity between MVD in benign tumours and malignant serous tumours, the higher MVD demonstrated in borderline mucinous tumours and the similar MVD observed in early-and late-stage serous tumours suggests that in ovarian tumours angiogenesis and tumour invasiveness and spread are not associated. Differences in MVD between tumour groups were observed in both the HVD and AVD regions. Most studies of MVD and prognosis determine microvessel counts only in regions of HVD and incorporating regions of AVD and low vessel density is thought to reduce the value of MVD as a prognostic indicator (Rak et al, 1995a) . Increased tumour cell shedding into the circulation is associated with increased tumour vascularization (Liotta et al, 1974; McCulloch et al, 1995) and the importance of the vascular 'hot spot' relates to its role as the likely site of tumour cell entry into the circulation and as an area of ongoing angiogenesis (Rak et al, 1995a; Weidner, 1995) . However, ovarian tumours rarely spread via the vasculature and the observation of greater MVD in both HVD and AVD regions of mucinous tumours suggests that angiogenesis is occurring throughout the ovarian tumour vasculature and may play a role in ongoing tumour growth rather than metastatic spread.
In this study antibodies to CD31 and CD34 highlighted similar numbers of microvessels. CD34 positivity of stromal elements has been reported previously (Chaubal et al, 1994 ) and in the current study was particularly apparent in benign ovarian tumours. Other studies have reported CD31 positivity of tumour cells and plasma (Chaubal et al, 1994; Weidner, 1995) ; however, we observed this phenomenon only occasionally. In this study, the JC70 antibody to CD3 1 was the most sensitive and specific marker of endothelial cells.
In both the mucinous and serous tumour groups examined in this study, blood vessel immunostaining using an antibody to FVIII-RA was significantly reduced relative to that seen with the other endothelial cell markers. Reduced blood vessel immunostaining using antibodies to FVIII-RA has been observed in a number of tumours (Toi et al, 1993; Hollingsworth et al, 1995) and is thought to be due to the reduced expression of FVIII-RA in smaller, less mature blood vessels (Schlingemann et al, 1991; Visscher et al, 1994) . The observation of reduced immunostaining in both the HVD and AVD regions of these tumours suggests that both regions contain populations of larger, mature blood vessels and smaller, less mature blood vessels, lending further support to the hypothesis that angiogenesis is occurring throughout the malignant and borderline ovarian tumour vasculature. It is noteworthy that, although FVIII-RA immunostaining was reduced in HVD regions of benign tumours, it was not to the level seen in borderline and malignant tumours and was not observed at all in AVD regions. It appears that the relative numbers of mature and immature vessels in benign tumours differ from those seen in borderline and malignant ovarian tumours. This finding and the observation of increased MVD in early-stage mucinous tumours may indicate that the level and control of angiogenesis differ between ovarian tumour types.
